![]() |
![]() |
|
![]() |
AHP is conducting trials to extend the use of Mylotarg to other forms of leukemia, as well as evaluating additional monoclonal antibodies in order to expand the use of this ground-breaking chemotherapy technology to breast cancer, lymphoma and prostate cancer. Mylotarg joins Neumega in AHP's global Oncology franchise product portfolio. Clinical studies with Neumega-recombinant interleukin-11, approved for use in the United States as a platelet growth factor for chemotherapy-induced thrombocytopenia in nonmyeloid malignancies-are further defining its role in managing thrombocytopenia in myeloid malignancies and viral disease. There currently are two other promising oncology research programs in Phase II clinical trials: CCI-779 and ERA-923. CCI-779 is designed to interrupt growth in a variety of tumors by inhibiting the action of a protein called mTOR, which appears to control a number of cell growth functions. It will be evaluated as a treatment for breast, prostate and renal cell cancers as well as soft tissue sarcoma. ERA-923 is a selective estrogen receptor modulator being developed as a treatment for breast cancer. |
|||
![]() |
"After being on dialysis
for four years because of kidney failure, I had a kidney transplant last
November. My mother donated one of her kidneys to me. I've been taking Rapamune
and other drugs since the operation, and everything is going well so far.
I feel stronger than I have in years - almost like I'm a new person." Irving Smith-Brooklyn, New York |
![]() |
|||||||||
|